FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225480307> ?p ?o ?g. }

• W4225480307 endingPage "3577" @default.
• W4225480307 startingPage "3577" @default.
• W4225480307 abstract "Macular telangiectasia, or MacTel, is a neurodegenerative disorder of the macula with a vascular component that is believed to be compensatory or secondary to the primary pathology. Classic clinical features include a loss of foveal translucency, crystalline deposits, intra-retinal cavitary lesions, loss of macular pigment, widened capillary spaces, right-angled vessels, pigment proliferation, perifoveal capillary ectasia, subretinal neovascularization (SRNV), and foveal atrophy. Two different forms, namely nonproliferative and proliferative, have been described. The original classification of MacTel was proposed by Gass, who divided it into four stages based on the clinical appearance.[1] Further classifications were based on Fluorescein angiography (FFA) leakage, optical coherence tomography (OCT) patterns, optical coherence tomography angiography (OCTA), and multimodal imaging. Most use circumferential involvement as a feature, starting with temporal involvement alone in early stages, and temporal and nasal and eventually the entire circumference with advanced stages of the disease. Various investigations that are performed to characterize the neurodegenerative component are Confocal blue reflectance, optical coherence tomography (OCT) - Muller cell function and ganglion cell involvement. Increased reflectance with confocal blue light occurs due to Muller cell damage as these cells transmit light through the retina and reduced macular pigment whose absorption maximum is in the blue range.[23] Macular pigment optic density assessment (MPOD), Fluorescence lifetime imaging (FLIO) – Macular pigment, photoreceptors. FLIO has been shown to detect changes in macular pigment with high contrast; thus, changes in macular pigment-specific lifetimes provide information about macular photoreceptors or possibly Müller cell loss.[4] OCT, including enface OCT – Ellipsoid zone (EZ) evaluation.[5] Multifocal ERG (MFERG), microperimetry – tests of function. Investigations that evaluate the vascular or angiogenic component include FFA – nonproliferative vs. proliferative MacTel, identification of SRNV OCT – EZ changes[5] OCTA – telangiectasia in superficial and deep capillary plexus (SCP and DCP), right-angled vessels, retinochoroidal anastomosis (RCA), SRNV, and vessel density. The neurodegenerative and vascular changes are believed to run in parallel.[3] Photoreceptors along the margins of EZ loss may be the initial source of signaling to the overlying vasculature leading to telangiectasia, and progressive loss of these photoreceptors may alter the signal. This, combined with loss of the Muller cell control of vascular growth, may lead to worsening of telangiectasia and the development of SRNV.[6] Methods of evaluating the severity of MacTel involve both qualitative and quantitative imaging features, in particular using OCT and OCTA. The EZ integrity measured on horizontal OCT images and the EZ area measured on en face OCT are representative of photoreceptor function. They are currently the most established markers for disease progression as well as assessment of response to interventional measures for the disease.[5] Retinal cavitations are caused by Muller cell damage and are known to change in character over time as a process of continuous remodeling. Large cavitations and extensive EZ loss are seen in eyes with poor vision, though cavitations may disappear with extensive end-stage atrophy. The lack of correlation between cavitation volume and EZ disruption has been observed, though cavitation volume has been shown to negatively correlate with BCVA.[7] OCTA enables us to obtain three-dimensional images of the perfused microvasculature in different retinal layers and choroid in a repeatable, noninvasive manner. OCTA studies of the retinal vasculature in MacTel have observed a decrease of capillary density, dilated and telangiectatic vessels, and the presence of RCA as well as SRNV in the outer retinal layers. Quantitative OCT-A data show a progressive rarefication of the retinal microvasculature in MacTel. The deep retinal plexus showed a progressive decrease of mean vessel density (VD), skeleton density (SD), and fractal dimension (FD) in the temporal parafoveal region in all disease stages. In the superficial layer, VD, SD, and FD were significantly decreased in the temporal parafoveal region of advanced and neovascular stages. The segments of the ETDRS grid were used as guides for measurement.[89] An article in this issue of the journal measured the area of vascular telangiectasia and correlated it with other clinical and structural parameters on OCT.[10] Measurement of the dimensions of the vascular abnormality has rarely been performed, possibly due to the difficulty in accurately identifying the exact borders of the same. The dynamic changes that occur in the natural history of the disease especially with respect to retinal cavitations on OCT emphasize the need to select imaging techniques and parameters that are reliable, reproducible, and easily interpreted. Severe vision loss is rare in MacTel and is mostly due to the neurodegenerative component, rarely the neovascular process. Findings in eyes with very poor vision from MacTel Natural History Observation Registration Study showed foveal photoreceptor layer atrophy with or without associated subretinal fibrosis; an affected area, termed MacTel area, limited to a horizontal diameter not exceeding the distance between the temporal optic disc margin and foveal center, and the vertical diameter not exceeding approximately 0.8 times this distance (except in eyes with large SRNV); reduced retinal thickness measures within the MacTel area; and less frequent retinal greying and more frequent hyperpigmentation compared with eyes with better BCVA.[11] Imaging in MacTel has given us a greater understanding of the pathogenesis of the disease, the presence of two parallel pathways of neurodegeneration and angiogenesis, and reliable biomarkers to assess response to treatment. Combined with our recent understanding of genetic influences that could dictate the phenotype, treatments could be directed toward managing the proliferative and nonproliferative forms of the disease." @default.
• W4225480307 created "2022-05-05" @default.
• W4225480307 creator A5056604090 @default.
• W4225480307 date "2021-01-01" @default.
• W4225480307 modified "2023-10-18" @default.
• W4225480307 title "Commentary: Imaging in macular telangiectasia type 2 – Correlating structural change with vision" @default.
• W4225480307 cites W2068155134 @default.
• W4225480307 cites W2071088624 @default.
• W4225480307 cites W2160436805 @default.
• W4225480307 cites W2617692241 @default.
• W4225480307 cites W2911166433 @default.
• W4225480307 cites W2946519991 @default.
• W4225480307 cites W2967119934 @default.
• W4225480307 cites W2982062141 @default.
• W4225480307 cites W3009495867 @default.
• W4225480307 cites W3019081745 @default.
• W4225480307 cites W4226454001 @default.
• W4225480307 doi "https://doi.org/10.4103/ijo.ijo_2086_21" @default.
• W4225480307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34826998" @default.
• W4225480307 hasPublicationYear "2021" @default.
• W4225480307 type Work @default.
• W4225480307 citedByCount "0" @default.
• W4225480307 crossrefType "journal-article" @default.
• W4225480307 hasAuthorship W4225480307A5056604090 @default.
• W4225480307 hasBestOaLocation W42254803071 @default.
• W4225480307 hasConcept C118487528 @default.
• W4225480307 hasConcept C120665830 @default.
• W4225480307 hasConcept C121332964 @default.
• W4225480307 hasConcept C2776403814 @default.
• W4225480307 hasConcept C2777093970 @default.
• W4225480307 hasConcept C2778024200 @default.
• W4225480307 hasConcept C2778075232 @default.
• W4225480307 hasConcept C2778257484 @default.
• W4225480307 hasConcept C2778818243 @default.
• W4225480307 hasConcept C2780248432 @default.
• W4225480307 hasConcept C2780827179 @default.
• W4225480307 hasConcept C30181142 @default.
• W4225480307 hasConcept C71924100 @default.
• W4225480307 hasConceptScore W4225480307C118487528 @default.
• W4225480307 hasConceptScore W4225480307C120665830 @default.
• W4225480307 hasConceptScore W4225480307C121332964 @default.
• W4225480307 hasConceptScore W4225480307C2776403814 @default.
• W4225480307 hasConceptScore W4225480307C2777093970 @default.
• W4225480307 hasConceptScore W4225480307C2778024200 @default.
• W4225480307 hasConceptScore W4225480307C2778075232 @default.
• W4225480307 hasConceptScore W4225480307C2778257484 @default.
• W4225480307 hasConceptScore W4225480307C2778818243 @default.
• W4225480307 hasConceptScore W4225480307C2780248432 @default.
• W4225480307 hasConceptScore W4225480307C2780827179 @default.
• W4225480307 hasConceptScore W4225480307C30181142 @default.
• W4225480307 hasConceptScore W4225480307C71924100 @default.
• W4225480307 hasIssue "12" @default.
• W4225480307 hasLocation W42254803071 @default.
• W4225480307 hasLocation W42254803072 @default.
• W4225480307 hasLocation W42254803073 @default.
• W4225480307 hasLocation W42254803074 @default.
• W4225480307 hasLocation W42254803075 @default.
• W4225480307 hasOpenAccess W4225480307 @default.
• W4225480307 hasPrimaryLocation W42254803071 @default.
• W4225480307 hasRelatedWork W1751609384 @default.
• W4225480307 hasRelatedWork W2001008446 @default.
• W4225480307 hasRelatedWork W2070166603 @default.
• W4225480307 hasRelatedWork W2074575505 @default.
• W4225480307 hasRelatedWork W2130134664 @default.
• W4225480307 hasRelatedWork W2286662940 @default.
• W4225480307 hasRelatedWork W3085761024 @default.
• W4225480307 hasRelatedWork W4210792680 @default.
• W4225480307 hasRelatedWork W4223586525 @default.
• W4225480307 hasRelatedWork W937346839 @default.
• W4225480307 hasVolume "69" @default.
• W4225480307 isParatext "false" @default.
• W4225480307 isRetracted "false" @default.
• W4225480307 workType "article" @default.